Pro-Pharmaceuticals, Inc. Selects SAFC to Ramp-up the Manufacture of DAVANAT(R) for Anticipated Use in Clinical Trials & Sales in Colombia

Published: May 03, 2011

NEWTON, Mass.--(BUSINESS WIRE)--Pro-Pharmaceuticals, Inc. (OTC: PRWP), the leader in Galectin Therapeutics, today announced it signed a multi-year agreement with SAFC®, the custom manufacturing business unit of Sigma-AldrichTM (Nasdaq: SIAL) to ramp-up the manufacture of the bulk drug substance or active pharmaceutical ingredient (API) for its lead product candidate, GM-CT-01 (DAVANAT®) for anticipated use in clinical trials and sales in Colombia, South America.

Back to news